Phase 3 Readout~month
Phase 3 Topline: A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in
- Drug
- ivonescimab
- Indication
- Metastatic Colorectal Cancer (CRC)
Other upcoming events for SMMT
PDUFA DatePDUFA Date: ivonescimab
Phase 3 ReadoutPhase 3 Topline: A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined With Pemetrex
Phase 3 ReadoutPhase 3 Topline: A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for th
Phase 3 ReadoutPhase 3 Topline: A Randomized, Double-blind, Multiregional Phase 3 Study of Ivonescimab Combined With Chemotherapy Ve
Patent ExpiryPatent/Exclusivity Expiry: DIFICID
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.